The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project

McIntyre, Roger S.; Soczynska, Joanna K.; Woldeyohannes, Hanna O.; Alsuwaidan, Mohammad; Danielle, S.; Carvalho, André F.; Jerrell, Jeanette M.; Dale, Roman M.; Gallaugher, Laura Ashley; Muzina, David J.; Kennedy, Sidney H.

doi:10.1016/j.comppsych.2014.08.051

Cited by 141 publications

(113 citation statements)

References 10 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…6 Evidence indicates that among adults with MDD, cognitive symptoms account for more variability in workplace performance than does total depressive symptom severity. 7 These observations support research underscoring the notion that cognitive dysfunction is a critical mediator of role impairment in MDD. 8 Results from 2 double-blind, randomized, placebo-controlled studies demonstrated a clinical benefit of vortioxetine on cognitive functioning in adults with MDD, including objective neuropsychological tests of executive functioning, speed of processing, verbal learning, and memory.…”

supporting

confidence: 59%

“…29 The observation that the antidepressant efficacy of duloxetine, as measured by MADRS, was not different in working patients may be a consequence of the fact that duloxetine has a more narrow beneficial effect on cognitive domains (ie, learning and memory) than does vortioxetine, consequently resulting in less opportunity for the potentiating effects of interpersonal and behavioral activation from being in the workplace setting. For example, perceived inattention has been shown to impair work performance, 7 and vortioxetine showed significant effects on tests (DSST, TMT-A, SRT, CRT) assessing attention and processing speed. It could therefore be speculated that there is a synergistic effect between the actions of vortioxetine on multiple cognitive domains and the behavioral activation effects of the working environment.…”

Section: Discussionmentioning

confidence: 99%

“…Results from both epidemiologic and clinical studies suggest that disturbances in cognitive functions in MDD are the principal and proximate determinants of workplace performance. 7 Consequently, interventions that are capable of targeting and improving cognitive functioning should very likely improve workplace performance/productivity. It has previously been reported that among individuals with past MDD, overall cognitive performance is more impaired in nonworking individuals than in those who are working.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre¹,

Florea²,

Tonnoir³

et al. 2016

J. Clin. Psychiatry

Self Cite

View full text Add to dashboard Cite

Objective: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD).Methods: Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ). FOCUS, conducted from December 2011 through May 2013, included adult patients with recurrent MDD according to DSM-IV-TR criteria. Change in depression severity (Montgomery-Asberg Depression Rating Scale [MADRS] total score) was analyzed using data from 3 additional short-term placebo-controlled studies (2 of which included duloxetine) and 1 relapse prevention study. Analyses were done according to patients' working status at baseline and workplace position. All analyses were made versus placebo. Results:In FOCUS, the effect versus placebo on the DSST was 5.6 for 10 mg and 5.0 for 20 mg (P < .001 for both doses) in working patients; the effect was 4.0 (P < .001 for both doses) in total study population. The effect remained significant when adjusting for change in MADRS. In patients with "professional" positions, the effect was 9.2 for 10 mg (P = .006) and 9.0 for 20 mg (P = .001). A similar pattern of results was also observed for TMT-A/B, Stroop, PDQ, and MADRS total score. The efficacy of duloxetine was not different in working patients (MADRS). Conclusions:The beneficial effects of vortioxetine on objective and subjective measures of cognitive functioning are greater in working patients with MDD; the observed benefits were independent of improvement in depressive symptoms. 6 Evidence indicates that among adults with MDD, cognitive symptoms account for more variability in workplace performance than does total depressive symptom severity. 7 These observations support research underscoring the notion that cognitive dysfunction is a critical mediator of role impairment in MDD. 8Results from 2 double-blind, randomized, placebo-controlled studies demonstrated a clinical benefit of vortioxetine on cognitive functioning in adults with MDD, including objective neuropsychological tests of executive functioning, speed of processing, verbal learning, and memory.9-11 These studies confirm and extend the results from an earlier double-blind, randomized, placebo-controlled, duloxetine-referenced study with vortioxetine in elderly (≥ 65 years) patients with MDD. 12The beneficial effect observed on measures of cognitive functioning with vortioxetine is of particular importance for individuals with MDD who are working and/or engaged in activities that place high demands on cognition (eg, educational pursuit). Because depression is primarily a disorder affecting people of working age, 13 it is important to understand how the effect of vortioxetine on cognit...

show abstract

supporting

confidence: 59%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre¹,

Florea²,

Tonnoir³

et al. 2016

J. Clin. Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cognitive dysfunction is prevalent, pervasive, and, in many cases, an enduring feature in adults with MDD. Moreover, selfreported cognitive impairment accounts for greater variability in workplace performance than does total depression symptom severity [McIntyre et al 2015]. There is a need to identify determinants of cognitive dysfunction in MDD.…”

Section: Discussionmentioning

confidence: 99%

The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project

McIntyre

Woldeyohannes

Soczynska

et al. 2016

Therapeutic Advances in Chronic Disease

Self Cite

View full text Add to dashboard Cite

Objectives:The aim of the study was to evaluate the prevalence of and illness characteristics in adults with major depressive disorder (MDD) with anxious distress specifier (ADS) enrolled in the International Mood Disorders Collaborative Project, which is a collaborative research platform at the Mood Disorders Psychopharmacology Unit, University of Toronto, Canada and the Cleveland Clinic, Cleveland, Ohio, USA. Methods: Data from participants who met criteria for a current major depressive episode as part of MDD (n = 830) were included in this post hoc analysis. Diagnostic and Statistical Manual Version-5-defined ADS was operationalized as the presence of at least two out of three proxy items instead of two out of five specifiers. Results: A total of 464 individuals (i.e. 56%) met criteria for ADS. There were no betweengroup differences in sociodemographic variables (e.g. gender, employment, marital status). Greater severity of illness was observed in adults with ADS as evidenced by a higher number of hospitalizations, higher rates of suicidal ideation, greater depressive symptom severity, greater workplace impairment, decreased quality of life, and greater self-reported cognitive impairment. Conclusions: Our findings underscore the importance of evaluating ADS in adults with MDD as its presence identifies a subpopulation with greater illness-associated burden and hazards.

show abstract

“…McIntyre et al [6] address the problem of the detrimental effect of MDD on workplace productivity by examining whether cognitive impairment in MDD could potentially be a factor leading to the problem. This study used data from the International Mood Disorders Collaborative Project (IMDCP) with a total of 1861 participants enrolled.…”

Section: Major Depressive Disorder Characteristicsmentioning

confidence: 99%

Latest Developments in Cognitive Functioning in Mood and Anxiety Disorders

Gould

Kaplan

Harvey

2015

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Cognitive impairments are well-documented features of mood and anxiety disorders. Recent developments in research on cognition, assessment techniques, treatments, and comorbidities in cognitive changes across major depression, bipolar disorder, and post-traumatic stress disorder (PTSD) are reviewed. Promising treatments have been reported but are tempered by self-reported cognitive performance and its minimal relationship to objective data. The need for objective assessment as well as assessment of subjective impressions of cognition is discussed. The use of assessment of performance-based measures of everyday functional skills in major depression, bipolar disorder, and PTSD is another critical development highlighted in the present review. The recent success of pharmacological treatments for cognitive impairments in major depressive disorder (MDD) is promising, yet the need for clinicians to assess and consider bias in their treatment outcome data is essential.

show abstract

The impact of cognitive impairment on perceived workforce performance: Results from the International Mood Disorders Collaborative Project

Cited by 141 publications

References 10 publications

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative Project

Latest Developments in Cognitive Functioning in Mood and Anxiety Disorders

Contact Info

Product

Resources

About